Kuvan (Sapropterin Dihydrochloride)

Sapropterin dihydrochloride supplies exogenous tetrahydrobiopterin (BH4), the natural cofactor required by phenylalanine hydroxylase. Increased BH4 stabilises the enzyme, enhancing its activity and promoting the conversion of phenylalanine into tyrosine, which reduces the accumulation of phenylalanine in the bloodstream.

The appropriate dose of Kuvan is determined individually by the prescribing physician. Dosing is based on the patient’s age, weight, baseline blood phenylalanine concentration, and response to therapy, and is adjusted through regular monitoring of phenylalanine levels.

Safety data for Kuvan in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and treatment decisions should be made in consultation with a specialist familiar with PKU management.

To order Kuvan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Kuvan is strict dietary management without pharmacologic therapy. Kuvan offers a pharmacologic option that can lower phenylalanine levels in BH4‑responsive patients, potentially reducing dietary restrictions. It is not a replacement for diet in non‑responsive individuals, and the choice depends on individual metabolic response.

Kuvan tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Kuvan is taken orally as a tablet. The tablet should be swallowed whole with water and can be taken with or without food, unless the prescribing clinician advises otherwise. Dosing times are usually aligned with regular blood phenylalanine monitoring.

The most serious adverse events include severe allergic reactions such as rash, itching, swelling, and anaphylaxis, as well as rare neurological events like seizures. Patients should seek immediate medical attention if they experience any signs of a serious hypersensitivity reaction.

Kuvan is contraindicated in individuals with a known hypersensitivity to sapropterin dihydrochloride or any of its excipients. Patients who are non‑responsive to BH4 supplementation, as determined by a BH4 loading test, should not use the drug, and it should be avoided in those with severe renal impairment without specialist guidance.